Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
about
Recent progress in pancreatic cancerCryosurgery for pancreatic cancerMeta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Pancreatic adenocarcinomaA Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathwayA meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?Oncolytic virotherapy for pancreatic cancer.A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinomaFOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersSurvival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study.Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11Role of taxanes in pancreatic cancer.Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study
P2860
Q24626346-5D14D246-07E1-4567-AC19-8F872C1CE801Q30434007-4484DFB8-BFDC-4366-9955-D5AC2A601F0EQ33373308-FC2D2FEC-536D-4E77-AD11-96884ABFA0B8Q33395577-20673D14-C08C-4CB4-95FA-F55ECE084E48Q33403498-7EE75ACF-F310-4388-A36C-15E2673CDD4CQ33418849-CDF31238-CEEB-4DFF-9AB0-3F6E5B03F935Q33427177-0788B14D-DE36-4621-9DF5-13776D4762F2Q33440500-D96011C9-B937-47FE-BCBD-CFDC8124A113Q34140498-4400ACC3-A691-4D03-8650-1400C2B9A7CCQ34294011-7AF676F4-CAF1-419C-9ACD-997AC4B43B08Q34439953-ECA4F6B2-F9C4-4B3F-A0AA-31C5BC3FE6DAQ34631279-5E870B70-6087-42AF-8CE5-125838599479Q34648037-ED4FC45D-ED7D-4D69-AD2F-46B478FB16F9Q34818494-6B296004-8251-4276-B3DB-E1C3B91ACA29Q34896040-F6656068-DA00-450D-8F2C-46BBA882436FQ35590996-6D4B2124-82A9-419F-B387-9216A21CD4C0Q35761097-F3D00021-D8FF-4471-8EF1-65208CD2B38FQ36214563-4B0C3298-59CF-479C-AE64-C66407668F1DQ36384541-321EBCD1-5169-44CB-9EC1-BEEC72849125Q38726733-AFBD4D7E-9059-44D3-9B97-4DE30520B613Q39938179-FC9676F9-D380-488A-9E27-05CBAD075147Q40913003-A7179513-AAB8-4047-B41D-680567F6D7B8Q42323567-0A8B9F1C-B637-4ADB-9E1E-24EE342DDB43Q48234878-C80A4A03-D85D-434A-8CAF-F0AB5578B79CQ48617362-903DF2D8-4A6F-44EE-AEF0-F91690B3C926Q58796906-2ACDA6F6-CEF7-41F9-A715-A03E5DCC924B
P2860
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized phase II study of g ...... ancreatic cancer: CALGB 89904.
@en
Randomized phase II study of g ...... ancreatic cancer: CALGB 89904.
@nl
type
label
Randomized phase II study of g ...... ancreatic cancer: CALGB 89904.
@en
Randomized phase II study of g ...... ancreatic cancer: CALGB 89904.
@nl
prefLabel
Randomized phase II study of g ...... ancreatic cancer: CALGB 89904.
@en
Randomized phase II study of g ...... ancreatic cancer: CALGB 89904.
@nl
P2093
P2860
P356
P1476
Randomized phase II study of g ...... ancreatic cancer: CALGB 89904.
@en
P2093
Donna Niedzwiecki
Donna R Hollis
Hedy L Kindler
Margaret A Tempero
Matthew H Kulke
Michael Cusnir
Peter C Enzinger
Richard M Goldberg
Robert J Mayer
Stefan M Gorsch
P2860
P304
P356
10.1200/JCO.2009.22.1309
P407
P577
2009-10-26T00:00:00Z